{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T18:07:59Z","timestamp":1794766079364,"version":"4.9.1"},"reference-count":110,"publisher":"Elsevier","isbn-type":[{"value":"9780128233573","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/b978-0-12-823357-3.00007-0","type":"book-chapter","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T21:46:49Z","timestamp":1706824009000},"page":"87-106","source":"Crossref","is-referenced-by-count":4,"title":["OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","article-title":"Current and emerging evidence-based treatment options in chronic migraine: a narrative review","volume":"20","author":"Agostoni","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0015","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jpain.2016.06.008","article-title":"The association between clinical characteristics of migraine and brain GABA Levels: an exploratory study","volume":"17","author":"Aguila","year":"2016","journal-title":"J Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","article-title":"An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study","volume":"20","author":"Ahmed","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/ene.14102","article-title":"Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies","volume":"27","author":"Ailani","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0030","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/ene.14028","article-title":"Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA","volume":"26","author":"Alpuente","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1468-1331.2001.00035.x","article-title":"Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions","volume":"8","author":"Aoki","year":"2001","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0040","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X 3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostilidis","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0045","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/jcu.20350","article-title":"A transcranial doppler study in interictal migraine and tension-type headache","volume":"35","author":"Arjona","year":"2007","journal-title":"J Clin Ultrasound"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0050","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system\u201440 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0055","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0060","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ane.12171","article-title":"OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program","volume":"129","author":"Aurora","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb9000","first-page":"27","article-title":"The impact of onabotulinumtoxinA on severe headache days: preempt 24-week pooled analysis [abstract no. PF28 plus poster]","volume":"56","author":"Aurora","year":"2016","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0070","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/head.12498","article-title":"Pharmacological trials in migraine: it's time to reappraise where the headache is and what the pain is like","volume":"55","author":"Barbanti","year":"2014","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0075","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3111\/13696998.2013.802694","article-title":"The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK","volume":"16","author":"Batty","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation","volume":"19","author":"Bendtsen","year":"2018","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1067\/mhn.2000.110960","article-title":"Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study","volume":"123","author":"Binder","year":"2000","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0090","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of OnabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","volume":"50","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0095","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12883-015-0353-x","article-title":"Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine","volume":"15","author":"Blumenfeld","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0105","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.toxicon.2016.11.024","article-title":"Efficacy and safety of onabotulinumtoxinA in an open-label study for the prophylactic treatment of chronic migraine in adult patients: compel","volume":"123","author":"Blumenfeld","year":"2016","journal-title":"Toxicon"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0110","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.pmrj.2017.08.061","article-title":"Poster 114: efficacy and safety of OnabotulinumtoxinA in an open-label study for the prophylactic treatment of chronic migraine in adult patients: COMPEL","volume":"9","author":"Blumenfeld","year":"2017","journal-title":"PM&R"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb9005","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pds.3920","article-title":"Pregnancy outcomes following exposure to onabotulinumtoxinA","volume":"25","author":"Brin","year":"2015","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/2193-1801-2-377","article-title":"Patients profiling for Botox\u00ae (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker","volume":"2","author":"Bumb","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0130","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1526-4610.2010.01796.x","article-title":"A multi-center double-blind pilot comparison of OnabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine","volume":"51","author":"Cady","year":"2010","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0140","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neuroscience.2017.03.049","article-title":"Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection","volume":"352","author":"Cai","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0145","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/head.12372","article-title":"CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine","volume":"54","author":"Cernuda-Moroll\u00f3n","year":"2014","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0150","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0333102414561873","article-title":"Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year?","volume":"35","author":"Cernuda-Moroll\u00f3n","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0155","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","article-title":"OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine","volume":"156","author":"Cernuda-Moroll\u00f3n","year":"2015","journal-title":"Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.abb.2012.05.016","article-title":"Inhibitory effect of botulinum toxin type A on the NANC system in rat respiratory models of neurogenic inflammation","volume":"524","author":"Chien","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0165","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0170","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","article-title":"Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Diener","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0175","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0180","doi-asserted-by":"crossref","first-page":"A98","DOI":"10.1186\/1129-2377-16-S1-A98","article-title":"O051. Chronic migraine and onabotulinumtoxinA: a prospective study on patients treated at the Headache Centre of the Padua University and analysis of possible predictors of responsivity","volume":"16","author":"Disco","year":"2015","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0185","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ane.12906","article-title":"Botulinum toxin: a review of the mode of action in migraine","volume":"137","author":"Do","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/head.13300","article-title":"A phase-by-phase review of migraine pathophysiology","volume":"58","author":"Dodick","year":"2018","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0195","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/jnnp.2007.134023","article-title":"Migraine prevention","volume":"7","author":"Dodick","year":"2007","journal-title":"Pract Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb9010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1526-4610.2005.05068.x","article-title":"Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study","volume":"45","author":"Dodick","year":"2005","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0200","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1526-4610.43.7s.4.x","article-title":"Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins","volume":"43","author":"Dolly","year":"2003","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0210","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ene.13523","article-title":"OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study","volume":"25","author":"Dom\u00ednguez","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0215","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/head.13211","article-title":"CGRP and PTX3 as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine: an observational study","volume":"58","author":"Dom\u00ednguez","year":"2018","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0220","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuropharm.2013.02.011","article-title":"Involvement of \u03bc-opioid receptors in antinociceptive action of botulinum toxin type A","volume":"70","author":"Drinovac","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0230","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1526-4610.2005.05067.x","article-title":"Duration of migraine is a predictor for response to botulinum toxin type A","volume":"45","author":"Eross","year":"2005","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0235","series-title":"Accessdata.fda.gov","author":"FDA Botox Label","year":"2021"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0240","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0245","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40263-020-00776-8","article-title":"OnabotulinumtoxinA in chronic migraine: a profile of its use","volume":"34","author":"Frampton","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0250","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40265-018-0894-6","article-title":"OnabotulinumtoxinA: a review in the prevention of chronic migraine","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0255","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.nrl.2017.09.008","article-title":"Evidencia y experiencia de b\u00f3tox en migra\u00f1a cr\u00f3nica: Recomendaciones para la pr\u00e1ctica cl\u00ednica diaria","volume":"34","author":"Gago-Veiga","year":"2019","journal-title":"Neurologia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb9015","first-page":"1211","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"16","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0260","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0265","first-page":"9","article-title":"The international classification of headache disorders, 2nd edition","volume":"24","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0275","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/0333102415621294","article-title":"Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: retrospective analysis of a US-based insurance claims database","volume":"36","author":"Hepp","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0280","first-page":"CD011616","article-title":"Botulinum toxins for the prevention of migraine in adults","volume":"6","author":"Herd","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0285","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1139\/Y07-018","article-title":"Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo","volume":"85","author":"Hou","year":"2007","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0290","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1067\/mjd.2000.105567","article-title":"Pharmacology of botulinum toxin","volume":"43","author":"Huang","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0295","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3389\/fnhum.2016.00497","article-title":"Brain changes in responders vs. non-responders in chronic migraine: markers of disease reversal","volume":"10","author":"Hubbard","year":"2016","journal-title":"Front Human Neurosci"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0300","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neulet.2016.02.020","article-title":"Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats","volume":"617","author":"Ibragi\u0107","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0305","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pain.2006.09.012","article-title":"Exploding vs. Imploding headache in migraine prophylaxis with botulinum toxin A","volume":"125","author":"Jakubowski","year":"2006","journal-title":"Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0310","doi-asserted-by":"crossref","first-page":"14316","DOI":"10.1021\/bi701564f","article-title":"Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E\u2020","volume":"46","author":"Kukreja","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0315","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/BJ20111117","article-title":"Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission","volume":"441","author":"Lawrence","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0320","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1213\/ANE.0b013e3181ffa1d7","article-title":"Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice","volume":"112","author":"Lee","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2016.01.054","article-title":"Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: a clinic-based prospective study","volume":"363","author":"Lee","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0330","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0335","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1212\/WNL.0b013e318232ab65","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine","volume":"77","author":"Lipton","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0340","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0333102416652092","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program","volume":"36","author":"Lipton","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0345","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuroscience.2011.04.026","article-title":"Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A","volume":"186","author":"Matak","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0350","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s10194-017-0784-4","article-title":"The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis","volume":"18","author":"Matharu","year":"2017","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0355","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/0333102417724150","article-title":"Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe","volume":"37","author":"Matharu","year":"2017","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0360","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","article-title":"A double-blind comparison of OnabotulinumtoxinA (BOTOX\u00ae) and topiramate (TOPAMAX\u00ae) for the prophylactic treatment of chronic migraine: a pilot study","volume":"49","author":"Mathew","year":"2009","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0365","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1526-4610.2007.00914.x","article-title":"Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache","volume":"48","author":"Mathew","year":"2007","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0370","doi-asserted-by":"crossref","first-page":"21338","DOI":"10.1016\/S0021-9258(19)36614-1","article-title":"Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action","volume":"267","author":"McMahon","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0375","series-title":"BOTOX 50 units powder for solution for injection\u2014summary of product characteristics (SmPC)\u2014History\u2014(emc)","author":"Medicines.org.uk","year":"2021"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0380","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review","volume":"30","author":"Natoli","year":"2009","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0385","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2012","journal-title":"J Neural Transm"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0390","series-title":"Overview | Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | Guidance | NICE","author":"Nice.org.uk","year":"2021"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb9020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10194-011-0294-8","article-title":"Experience with onabotulnumtoxinA (BOTOX) in chronic refractorymigraine: focus on severe attacks","volume":"12","author":"Oterino","year":"2011","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0395","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ana.24665","article-title":"Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: implications for extracranial origin of headache","volume":"79","author":"Perry","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0400","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-2952(00)00260-4","article-title":"Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms","volume":"59","author":"Purkiss","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0405","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fneur.2020.00417","article-title":"Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and OnabotulinumtoxinA: a dual-center retrospective observational study","volume":"11","author":"Raffaelli","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0410","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1468-2982.2007.01315.x","article-title":"A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (boNTA) for the prophylaxis of episodic migraine headaches","volume":"27","author":"Relja","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0415","doi-asserted-by":"crossref","first-page":"703","DOI":"10.7205\/MILMED-D-13-00477","article-title":"OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report","volume":"179","author":"Robinson","year":"2014","journal-title":"Mil Med"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0420","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1186\/1129-2377-14-S1-P216","article-title":"Real-world economic impact of OnabotulinumtoxinA in patients with chronic migraine","volume":"14","author":"Rothrock","year":"2013","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0425","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/head.13653","article-title":"FORWARD study: evaluating the comparative effectiveness of OnabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0430","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10072-014-1741-5","article-title":"The cost effectiveness of Botox in Italian patients with chronic migraine","volume":"35","author":"Ruggeri","year":"2014","journal-title":"Neurol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0435","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10194-011-0339-z","article-title":"Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study","volume":"12","author":"Sandrini","year":"2011","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0440","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","article-title":"Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design","volume":"18","author":"Serrano","year":"2017","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0445","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10408410590912952","article-title":"Clostridium botulinum: a bug with beauty and weapon","volume":"31","author":"Shukla","year":"2005","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0450","first-page":"973","article-title":"Preventive migraine treatment. CONTINUUM: lifelong learning","volume":"21","author":"Silberstein","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0455","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1526-4610.2000.00066.x","article-title":"Botulinum toxin type A as a migraine preventive treatment","volume":"40","author":"Silberstein","year":"2000","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0460","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1468-2982.2006.01114.x","article-title":"Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study","volume":"26","author":"Silberstein","year":"2006","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0465","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","article-title":"Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial","volume":"47","author":"Silberstein","year":"2007","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0470","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline","volume":"331","author":"Silberstein","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0475","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0480","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0485","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0490","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0495","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1129-2377-15-31","article-title":"The impact of headache in Europe: principal results of the Eurolight project","volume":"15","author":"Steiner","year":"2014","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0500","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","article-title":"Aids to management of headache disorders in primary care (2nd edition)","volume":"20","author":"Steiner","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0505","unstructured":"The Pharmaceutical Benefits Scheme 2021. [online] Available at: <https:\/\/www.pbs.gov.au\/pbs\/industry\/listing\/elements\/pbac-meetings\/psd\/2013-07\/botulinum> [Accessed 2 February 2021]."},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0510","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1526-4610.1990.hed3004209.x","article-title":"Transcranial doppler evaluation of common and classic migraine. Part II. Ultrasonic features during attacks","volume":"30","author":"Thie","year":"1990","journal-title":"Headache"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0515","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s10194-020-01196-1","article-title":"OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients","volume":"21","author":"Wong","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0520","series-title":"Atlas of headache disorders and resources in the world","author":"World Health Organization","year":"2011"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0525","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0333102416636843","article-title":"Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors\u2019 responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle?","volume":"36","author":"Zhang","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/B978-0-12-823357-3.00007-0_bb0530","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ejphar.2016.09.019","article-title":"Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain","volume":"791","author":"Zychowska","year":"2016","journal-title":"Eur J Pharmacol"}],"container-title":["Handbook of Clinical Neurology","Migraine Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128233573000070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128233573000070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T13:19:40Z","timestamp":1753967980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128233573000070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780128233573"],"references-count":110,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-823357-3.00007-0","relation":{},"ISSN":["0072-9752"],"issn-type":[{"value":"0072-9752","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}